Notícias e Atividades da Monte Rosa Therapeutics

Monte Rosa Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Monte Rosa Therapeutics é uma empresa listada sob o símbolo GLUE (US).

Veja o organograma con seus 18 executivos principais

Biografias mais buscadas da Monte Rosa Therapeutics

• Markus Warmuth, Chief Executive Officer and Director
• Kimberly Blackwell, Director
• Christine Siu, Director

Recentes movimentos de executivos em Monte Rosa Therapeutics

• Eric Hughes, ingressou na Companhia como Director  (Notícia publicada em 13 de dezembro de 2024).

Criar um alerta
para seguir os movimentos de executivos da Monte Rosa Therapeutics.

Monte Rosa Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).
• SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Monte Rosa Therapeutics

• Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs - Monte Rosa Therapeutics
• Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 - Monte Rosa Therapeutics
• Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 - Monte Rosa Therapeutics
• Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors - Monte Rosa Therapeutics
• View more press releases Close

Redes sociais sobre Monte Rosa Therapeutics

• Monte Rosa Therapeutics na Wikipedia, Google News e Yahoo Finance
• Monte Rosa Therapeutics na LinkedIn, Twitter e YouTube